Aptinyx has concluded the enrolment of subjects in the ongoing Phase IIb clinical trial of its new oral therapy, NYX-2925, to treat painful diabetic peripheral neuropathy (DPN).
A new N-methyl-D-aspartate (NMDA) receptor positive allosteric modulator, NYX-2925 is presently being analysed in a Phase II trial to treat chronic pain.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The randomised, placebo-controlled, double-blind Phase IIb trial will analyse the efficacy and safety of NYX-2925 in subjects with advanced painful DPN.
After the screening period, qualified subjects will be categorised to receive once-daily doses of either 50mg NYX-2925 or placebo during the treatment duration.
The change from baseline in weekly average daily pain score over a duration of 12 weeks as assessed on the ten-point numeric rating scale will be the primary goal of the trial.
In the trial, several secondary and exploratory goals linked to pain and the quality of life of the subject will also be analysed.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSubjects who complete the 12-week treatment duration will be subsequently followed up for safety after 30 days.
Aptinyx anticipates reporting data from the trial in the early-to-mid-second quarter of next year.
Aptinyx CEO Norbert Riedel said: “We look forward to completing the study and reporting results next year, which, if positive, would support the late-stage clinical development of NYX-2925 in painful DPN.
“This readout will be the first of the multiple Phase II data catalysts we expect across our development pipeline over the next 24 months.”
A neuropathic pain condition, painful DPN affects nearly 7.5 million individuals in the US.
It develops in 60%-70% of diabetes patients when chronically increased levels of glucose injure nerves and disrupt information transmission between the central nervous system and other body parts.
Earlier this year, Aptinyx restarted recruiting and screening participants in a Phase II trial of NYX-2925 to treat painful DPN patients.
